Executive record

Stuart C. Dorman

Director at IDEAYA Biosciences, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:stuart-c-dorman-idyaVersion: public-0As of: 2026-09-30

Not yet claimed11 published Claims5 sources
  • Executive
  • Director

Key Claims

Biography

Has served as Chief Commercial Officer since December 2024, with prior roles as VP and US Oncology Business Unit Head at Gilead Sciences and VP of Oncology Worldwide Commercialization at Bristol Myers Squibb. Earlier in his career was a Senior Consultant and Manager at Trinity Partners LLC, a life sciences strategy consulting firm.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. Current · dates not publishedChief Commercial Officer · IDEAYA Biosciences, Inc.
  2. 2026 to end not publishedExecutive title: Chief Commercial Officer · Organization not publishedIDYA DEF 14A executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

5 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. IDYA DEF 14A executive officers

    sec filing · Source published: Apr 29, 2026 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at IDEAYA Biosciences, Inc. · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Chief Commercial Officer · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  2. Open source

    sec proxy · Source published: Apr 29, 2026 · Retrieved: Sep 2, 2026

    Supports 1 claim
    • Professional Role: Director at IDEAYA Biosciences, Inc. · Claim reviewed: Sep 6, 2026

  3. Open source

    sec def 14a · Source published: Apr 29, 2026 · Retrieved: Sep 6, 2026

    Supports 1 claim
    • Professional Role: Chief Commercial Officer at IDEAYA Biosciences, Inc. · Claim reviewed: Sep 6, 2026

  4. IDYA executive roster source

    sec filing · Source published: Date unavailable · Retrieved: May 3, 2026

    Supports 5 claims
    • AI expertise: AI expertise: not identified in the cited filing · Claim reviewed: May 3, 2026
    • AI governance relevance: AI governance relevance: not identified in the cited filing · Claim reviewed: May 3, 2026
    • Executive company: Executive at IDEAYA Biosciences, Inc. · Claim reviewed: May 15, 2026
    • Executive function: Other Executive (OTHER_EXECUTIVE) · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Chief Commercial Officer · Claim reviewed: May 15, 2026

  5. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of IDEAYA Biosciences, Inc. · Claim reviewed: Sep 6, 2026